Clinical Trials Directory

Trials / Completed

CompletedNCT00723437

Evaluation of the Efficacy of Acitretin Therapy for Nail Psoriasis

Evaluation of Nail Psoriasis Severity Index (NAPSI) and Modified Napsi in Patients With Nail Psoriasis Treated With Acitretin

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
36 (actual)
Sponsor
Istituti Fisioterapici Ospitalieri · Academic / Other
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

Objective: Efficacy of systemic retinoid therapy of nail psoriasis has never been assessed objectively. Evaluate therapeutic efficacy of acitretin in patients with isolated nail psoriasis. Design: Open-study on thirty-six patients with moderate to severe nail psoriasis treated with acitretin. Participants: Patients included 27 men and 9 women (mean age 41) with nail psoriasis. Intervention: Therapy consisted of acitretin 0.2 to 0.3 mg/Kg/day for 6 months. Main Outcome Measure(s): Clinical evaluation, NAPSI and modified NAPSI scores before therapy, every 2 months during therapy and 6 months after treatment.

Detailed description

The Nail Psoriasis Severity Index (NAPSI) has been designed and successfully implemented to grade severity of psoriatic nail disease. Moreover, the utilization of the NAPSI score and a modified version of this severity index score as an instrument to monitor response to therapy has been recently documented in the medical literature .This open study involves thirty-six patients with moderate to severe nail psoriasis treated with low-dose acitretin from January 2005 to January 2007.Acitretin was given at the dosage of 0.2 to 0.3 mg/Kg/day for 6 months. Laboratory investigations and clinical evaluation, which included photographic record and scoring of NAPSI and modified NAPSI, were performed every 2 months. Investigator evaluation was performed using a 0 (no improvement) to 3 (cleared or almost cleared) score Treatment satisfaction by patients and tolerability were assessed at each visit. All patients were followed for at least 6 months after the end of treatment.

Conditions

Interventions

TypeNameDescription
DRUGacitretinAcitretin at the dosage of 0.2 to 0.3 mg/Kg/day for 6 months.

Timeline

Start date
2005-01-01
Primary completion
2007-01-01
Completion
2008-07-01
First posted
2008-07-28
Last updated
2008-07-28

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT00723437. Inclusion in this directory is not an endorsement.